Physician profile
Alan I Kanter
NPI 1184678328
$526.70
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $42.62 · 2021: $140.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $128.16 | 2019 | |
| Supernus Pharmaceuticals, INC. | $125.00 | 2021 | |
| Pfizer INC. | $66.54 | 2019 | |
| Arbor Pharmaceuticals, INC. | $50.69 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $39.35 | 2019-2020 | |
| Glaxosmithkline, LLC. | $27.85 | 2019-2021 | |
| Neos Therapeutics, LP | $22.66 | 2019 | |
| Adlon Therapeutics L.P. | $15.33 | 2019 | |
| Merck Sharp & Dohme LLC | $14.00 | 2019 | |
| Tris Pharma INC | $13.40 | 2019 | |
| Abbvie INC. | $12.74 | 2019 | |
| Shire North American Group INC | $10.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Kanter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.